SERA SERA
Company Profile ↓Company Overview
SERA (SERA) is a publicly traded company listed on with a market capitalization of $77.89M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 34.2% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $81.00K (+5.2% YoY); net profit $-31.93M.
- Trailing 12 Months Year-on-year growth — revenue +5.2%.
- 5-Year Trend Long-term compounding — revenue CAGR 34.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 34.16% |
| 1 Year: | 5.19% |
Stock Price Performance
| 1 Year: | -25.93% |
| 6 Months: | -29.08% |
| 3 Months: | +6.38% |
| 1 Month: | -0.50% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)48.30 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 34.2% over 5 years.
CONS
- Trading 46.7% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 6.00K | 5.00K | 13.00K | 20.00K | 23.00K | 38.00K | 78.00K | 87.00K | 100.00K | 123.00K | 42.00K | 0 | 24.00K | 29.00K | 38.00K | 17.00K | 16.00K | 10.00K | 14.00K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 40.00K | 41.00K | 41.00K | 42.00K | 42.00K |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.00K | -24.00K | -25.00K | -32.00K | -28.00K |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 9.25M | 9.30M | 8.96M | 8.92M | 9.33M |
| Operating Income | - | -4.28M | -4.64M | -6.03M | -7.38M | -9.44M | -12.30M | -11.75M | -11.19M | -11.33M | -11.46M | -8.18M | -9.10M | -9.25M | -8.86M | -9.25M | -9.32M | -8.98M | -8.95M | -9.36M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -7.97M | -7.81M | -7.57M | -7.64M | -8.20M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.00K | 2.00K | 2.00K | 1.00K | 2.00K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -8.19M | -8.05M | -7.81M | -7.88M | -8.40M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -4.70M | -4.71M | -5.07M | -6.36M | -6.31M | -9.86M | -12.21M | -11.52M | -10.71M | -10.56M | -10.54M | -7.21M | -8.10M | -8.30M | -7.92M | -8.19M | -8.05M | -7.81M | -7.88M | -8.40M |
| Diluted EPS | - | - | -3.30 | -3.55 | -3.17 | -0.39 | -0.40 | -0.37 | -0.35 | -0.34 | -0.34 | -0.23 | -0.25 | -0.25 | -0.24 | -0.20 | -0.16 | -0.16 | -0.16 | -0.17 |
| R&D Expense | - | 1.75M | 1.89M | 2.40M | 2.82M | 2.72M | 3.32M | 3.26M | 4.18M | 4.10M | 3.69M | 3.54M | 3.68M | 4.41M | 3.50M | 3.33M | 3.34M | 3.28M | - | 3.03M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 25.00K | - | 268.00K | 306.00K | 77.00K | 81.00K |
| Cost of Revenue | - | - | 193.00K | 210.00K | 82.00K | 164.00K |
| Gross Profit | - | - | 75.00K | 96.00K | -5.00K | -83.00K |
| Operating Expenses | - | - | 45.73M | 39.92M | 36.63M | 36.42M |
| Operating Income | -17.97M | - | -45.65M | -39.82M | -36.63M | -36.50M |
| EBITDA | - | - | -43.37M | -35.29M | -32.04M | -30.98M |
| Interest Expense | - | - | 61.00K | 55.00K | 28.00K | 9.00K |
| Pretax Income | - | - | -44.19M | -36.24M | -32.90M | -31.93M |
| Tax Provision | - | - | - | - | - | - |
| Net Income | -19.85M | - | -44.19M | -36.24M | -32.90M | -31.93M |
| Diluted EPS | -12.76 | - | -1.43 | -1.16 | -0.99 | -0.67 |
| R&D Expense | 7.78M | 11.02M | 14.24M | 15.22M | 14.73M | 13.17M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 14.80M | - | 116.33M | 95.44M | 72.58M | 101.93M |
| Current Assets | - | - | - | 90.12M | 61.34M | 47.60M | 40.77M |
| Cash & Equivalents | - | 13.53M | - | 29.88M | 3.88M | 4.04M | 3.94M |
| Inventory | - | - | - | - | - | - | - |
| Receivables | - | - | - | 113.00K | 160.00K | 34.00K | 12.00K |
| Total Liabilities | - | 12.33M | - | 17.39M | 25.28M | 24.77M | 26.52M |
| Current Liabilities | - | 11.24M | - | 15.54M | 24.44M | 24.77M | 24.19M |
| Long Term Debt | - | - | - | - | - | - | - |
| Total Debt | - | - | - | 2.83M | 1.86M | 840.00K | 2.34M |
| Total Equity | -106.62M | -125.57M | - | 98.94M | 70.16M | 47.80M | 75.41M |
| Shares Outstanding | - | - | - | 31.02M | 31.70M | 34.17M | 38.94M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -16.87M | - | -34.61M | -27.19M | -14.19M | -25.62M |
| Investing Cash Flow | -149.00K | - | 5.55M | 438.00K | 11.74M | -28.50M |
| Financing Cash Flow | 9.16M | - | 5.00K | 752.00K | 2.61M | 54.03M |
| Capital Expenditure | -149.00K | - | -791.00K | -128.00K | -1.10M | -726.00K |
| Free Cash Flow | -17.02M | - | -35.40M | -27.32M | -15.29M | -26.35M |
| Net Change in Cash | - | - | -29.05M | -26.00M | 163.00K | -99.00K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | 28.0% | 31.4% | -6.5% | -102.5% |
| Operating Margin % | -71,884.0% | - | -17,034.3% | -13,013.4% | -47,577.9% | -45,066.7% |
| Net Margin % | -79,392.0% | - | -16,487.3% | -11,843.8% | -42,724.7% | -39,417.3% |
| ROE % | 15.8% | - | -44.7% | -51.7% | -68.8% | -42.3% |
| ROCE % | -505.7% | - | -45.3% | -56.1% | -76.6% | -47.0% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SERA
SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF SECOND QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON AUGUST 12, 2026
Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced it will report second quarter f…
PRIME SUBGROUP ANALYSIS DEMONSTRATES 22% REDUCTION IN NICU ADMISSIONS IN FIRST-TIME PREGNANCIES USING PreTRM® Test-GUIDED CARE
Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information, today announced publication of a new subgroup analysis from the PRIME r…
SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF MARK CAPONE TO ITS BOARD OF DIRECTORS
Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Mark Capone will join its …
SERA PROGNOSTICS COLLABORATES ON ARPA-H AWARD TO ADVANCE POINT-OF-CARE DIAGNOSTIC FOR SAFER BIRTH
Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information, today announced its participation in a multi-institutional research pro…
SERA APPLAUDS ILLINOIS INITIATIVE TO EXPAND MEDICAID COVERAGE FOR PROTEOMIC BLOOD TESTING IN PREGNANCY
Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information, today acknowledged recent legislative action in Illinois aimed at expan…
All You Need to Know About Sera Prognostics (SERA) Rating Upgrade to Buy
Sera Prognostics (SERA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
SERA — Frequently Asked Questions
What is the current share price of SERA?
As of 2026-08-05 17:25 PDT, SERA trades at $2.00 on NASDAQ/NYSE. Its 52-week range is $1.59 to $3.75.
What is the market capitalisation of SERA?
SERA has a market capitalisation of $77.89M on NASDAQ/NYSE.
What is the P/E ratio of SERA?
SERA trades at a trailing price-to-earnings (P/E) ratio of -2.99. Its price-to-book (P/B) ratio is 1.03.
What is the return on equity (ROE) of SERA?
SERA has a return on equity (ROE) of -42.34%. Its return on capital employed (ROCE) is -46.95%.
Is SERA a good stock to buy?
This page provides a data-driven analysis of SERA, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.